24 Nov

2021 AGM - Executive Chairmans Presentation

24 November 2021 Growth through medtech innovation Sales & Distribution Identifying and distributing high growth medtech products Product Innovation Transforming ideas into commercial products Venture Investment Investing in early - stage high potential medical device companies 2 24 November 2021 Our strategic focus (1) World Health Organisation June 2021 (2) Global Industry Analysts, Inc Reports - April 2021 CVD is the No 1 Cause of death globally 18 million Annual global CVD related deaths 1 85% CVD deaths caused by heart attacks or stroke 1 $70B+ CVD device market by 2027 2 3 Three or more CVD devices producing +$50m revenues p.a. in 2025 24 November 2021 Our objective 2021 2025 Design Services Investment Returns Product Sales Meeting our objective of becoming a global medtech product company will reshape our revenue mix and earnings. 4 Progressing product launches in CY22 24 November 2021 Realising our objective Product 1 Implantable Monitoring Device AngelMed Guardian FDA approved implantable continuous heart monitor • 45% of heart attacks are silent • <1 hour surgery, like a pacemaker implant • Significantly reduces false positive hospital visits Product 2 Cardiovascular Surgery Device Phyzhon FFR Coronary guidewire with integrated pressure sensor • Improve stent placement procedures • Better patient experience • Reduces treatment time Future product expansion We are evaluating several new opportunities to build on our product portfolio Small percentage market capture could deliver A$50m+ revenues p.a. 5 Hydrix is fast emerging as a global medtech company Advancing our global medtech strategy 24 November 2021 6 FY21 & YTD FY22 Highlights Despite COVID causing many disruptions & delays, we achieved significant milestones. Highlights from FY21 and YTD FY22 include: • Delivered FY21 $7.5m revenues • Achieved FIRST ever sales and implants of the AngelMed Guardian • Signed SECOND exclusive cardiac device distribution agreement • Submitted regulatory approvals in FIVE jurisdictions for AngelMed Guardian • Appointed several senior sales & business development personnel • Appointed Mr Paul Lewis as Non - Executive Director • Recapitalised the company, paying down $4.5m debt • Received FOUR International Good Design Awards • A growing international market recognition & presence Progressing towards first commercial product sales 24 November 2021 7 CY22 Outlook CY22 key milestone news flow beginning the first half: • Outcome of an Australian Human Ethics Committee review of The Guardian (in progress) • Outcomes of AngelMed Guardian TGA (AUS) and HSA (SNG) regulatory approval process • First sales & implants of AngelMed Guardian in Australia, Singapore & New Zealand • Commence First - in - Human Trials of Phyzhon cardiac catheter guidewire • Appoint SE Asia sub - distributors for AngelMed Guardian and outcomes of regulatory approvals for Malaysia, Hong Kong, Thailand • Client services YTD revenue trending to YoY growth +40% • Cash inflow of ~ $2.3m if HYD $0.12c options are exercised • Uplift in v aluations across the Ventures portfolio 24 November 2021 Summary Product sales into the US $70B CVD market commencing CY2022 World class team focused on improving a billion lives Board & management with a proven track record 8 This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to inv est ors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Company. The document is not intended to con stitute an invitation or an inducement to engage in any investment activity. The presentation is not intended to constitute investment advice and should not be relied upon as such. This docume nt is not intended as an offer or recommendation with respect to the purchase or sale of any securities in the Company. The content and graphical illustrations contained in the presentation are provided for information purposes and should not be re lied upon to form any investment decisions or to predict future performance. The Company is wholly reliant upon third parties for the accuracy and completeness of the information in the pre sen tation and has no duty of care owed to you in relation to such information. Although the information expressed is provided in good faith and the Company believes that its expectations are bas ed on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those included in the forward - look ing statements include amongst others, unforeseen delays in product development, the timing and extent of any changes in the associated technology and the ability of the Company to meet its sta ted business goals. Prospective investors should make their own independent evaluation of an investment in the Company or seek advice from their fin ancial adviser, accountant, lawyer, stockbroker or other professional adviser before making any investment decision. Nothing in this presentation should be construed as financial product advice, whe ther personal or general, for the purposes of Section 766B of the Corporations Act, or otherwise. This presentation does not amount to, involve or imply a recommendation or a statement of opi nio n in respect of whether to buy, sell or hold a financial product. Neither Hydrix nor any of its or their associates or any of the Company’s directors’ (Hydrix Group) shall have any liability wha tsoever for: (a) investment advice; (b) a recommendation to enter into any transaction or strategy; (c) advice that a transaction or strategy is suitable or appropriate; (d) the primary basis for any inv estment decision; (e) a representation, warranty, guarantee with respect to the legal, accounting, tax or other implications of any transaction or strategy; or (f) to cause the Hydrix Group to be an adviso r o r fiduciary of any recipient of this report or other third party. None of the Hydrix Group shall be responsible for or have any liability to you for losses or damages (whether consequential, incidental o r o therwise) arising in any way for errors or omissions in, or the use of or reliance upon the information contained in this document. To the greatest extent permitted by law, we exclude all conditions and warranties that might otherwise be implied by law with respect to the document, whether by operation of law, statute or otherwise, including as to their accuracy, completeness or fitness for purp ose . Unauthorised copying of this document is prohibited. 24 November 2021 10
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Hydrix Limited (ASX:HYD) when you join Listcorp.